These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3099425)

  • 1. Assay of factor VIII concentrates: comparison of the chromogenic and two-stage clotting assays.
    Hubbard AR; Curtis AD; Barrowcliffe TW; Edwards SJ; Jennings CA; Kemball-Cook G
    Thromb Res; 1986 Dec; 44(6):887-91. PubMed ID: 3099425
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical application of a chromogenic substrate method for determination of factor VIII activity.
    Rosén S; Andersson M; Blombäck M; Hägglund U; Larrieu MJ; Wolf M; Boyer C; Rothschild C; Nilsson IM; Sjörin E
    Thromb Haemost; 1985 Dec; 54(4):818-23. PubMed ID: 3937277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
    Barrowcliffe TW; Raut S; Sands D; Hubbard AR
    Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.
    Mikaelsson M; Oswaldsson U
    Semin Thromb Hemost; 2002 Jun; 28(3):257-64. PubMed ID: 12098085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study.
    Cinotti S; Longo G; Messori A; Morfini M; Blomback M; Schimpf K; Schumacher K; Kjellman H; Novakova-Banet A; Delvos U
    Thromb Res; 1991 Feb; 61(4):385-93. PubMed ID: 1905848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of clotting factor VIII activity in mammals using the one-stage clotting and the chromogenic methods].
    Lutze G; Lutze G; Kutschmann K; Schröpel M
    Berl Munch Tierarztl Wochenschr; 2002; 115(7-8):297-302. PubMed ID: 12174728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
    Lundblad RL; Kingdon HS; Mann KG; White GC
    Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rebuttal: Issues with the assay of factor VIII activity in plasma and factor VII concentrates.
    Rosén S
    Thromb Haemost; 2001 Oct; 86(4):1132-3. PubMed ID: 11686346
    [No Abstract]   [Full Text] [Related]  

  • 9. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of coagulation factor VIII activity by a chromogenic substrate method on STA, an automated coagulation analyzer.
    Kleinveld HA; Andersson NE; van Voorthuizen H; den Hartog J; de Groot PG
    Scand J Clin Lab Invest; 1999 Aug; 59(5):335-41. PubMed ID: 10533845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of factor VIII activity of efraloctocog alfa with commercially available one-stage clotting and chromogenic assays: Results from the Belgian national External Quality Assessment Scheme.
    Van Blerk M; Chatelain B; Devreese K; Jacquemin M; Jochmans K; Mullier F; Soumali MR; Broeders S
    Int J Lab Hematol; 2019 Feb; 41(1):e20-e22. PubMed ID: 30291733
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
    Mazurier C; Parquet-Gernez A; Goudemand M
    Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogenic factor VIII activity assay.
    Moser KA; Adcock Funk DM
    Am J Hematol; 2014 Jul; 89(7):781-4. PubMed ID: 24676945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
    Kitchen S; Kershaw G; Tiefenbacher S
    Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogenic Factor VIII Assays for Improved Diagnosis of Hemophilia A.
    Rodgers S; Duncan E
    Methods Mol Biol; 2017; 1646():265-276. PubMed ID: 28804835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
    Ingerslev J; Jankowski MA; Weston SB; Charles LA;
    J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-stage vs. chromogenic assays in haemophilia A.
    Potgieter JJ; Damgaard M; Hillarp A
    Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
    Peyvandi F; Oldenburg J; Friedman KD
    J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a simple chromogenic factor VIII assay for clinical use.
    Wagenvoord RJ; Hendrix HH; Hemker HC
    Haemostasis; 1989; 19(4):196-204. PubMed ID: 2509307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.